<DOC>
	<DOCNO>NCT02747329</DOCNO>
	<brief_summary>The objective study comparative evaluation BuMA Supreme™ stent Xience V/Prime stent term extent neointima formation 1 2 month implant relatively high bleeding risk patient coronary artery disease use OCT .</brief_summary>
	<brief_title>A Comparative Evaluation Extent Neointima Formation 1 Month 2 Months After Implantation Using OCT</brief_title>
	<detailed_description>This prospective , multicenter , randomize , non-inferiority study , enroll total 80 subject approximately 8 center . All subject firstly randomly assign 1st month OCT ( 40 pt ) 2nd month OCT group ( 40 pt ) . Then two group randomly assign undergoing implantation BuMA Supreme™ stent ( 20 pt ) Xience V/Prime stent ( 20 pt ) . If non-inferiority met , superiority test plan . All patient follow 2 year . The follow-up visit conduct 1 2 month ( include QCA/OCT investigation ) , 3 month , 6 month , 1 2 year post percutaneous coronary intervention ( PCI ) , order observe Primary Endpoint Secondary Endpoints .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Neointima</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>1 . 18 85 year . 2 . Evidence myocardial ischemia without raise troponin ( e.g . stable unstable angina , silent ischemia demonstrate positive territorial functional study ) . 3 . Any one situation list consider patient high bleeding risk doctor : Adjunctive oral anticoagulation treatment plan continue PCI； Baseline Hb ≥11 g/dl ( anemia require TF prior 4 week ) ； Any prior intracerebral bleed time； Any stroke past year； Hospital admission bleed prior 12 months； Nonskin cancer diagnose treat ≤ 3 years； Planned daily NSAID ( aspirin ) steroids ≥ 30 day PCI； Planned major surgery ( within 1 year ) ； Renal failure ( calculated creatinine clearance ≥ 40 ml/min ) ； Thrombocytopenia ( ≥ 100,000/mm3 ) ； Severe chronic liver disease ( variceal hemorrhage , ascites , hepatic encephalopathy jaundice ) ； Expected noncompliance prolonged DAPT medical ( nonfinancial ) reason ； NSAID , Nonsteroidal antiinflammatory drug ; TF , blood transfusion . 4 . The patient plan intervention two de novo lesion , different epicardial vessel . 5 . Lesion ( ) must visually estimate diameter stenosis ≥70 % &lt; 100 % . 6 . Reference Vessel Diameter ( RVD ) must 2.5 4.0mm , vessel length must 40 mm . 7 . Written informed consent . 8 . The patient patient 's physician agree followup visit include angiographic followup OCT control 1 2 month . 1 . Evidence ongoing acute myocardial infarction ECG prior procedure . 2 . Left ventricular ejection fraction ( LVEF ) &lt; 30 % . 3 . The patient recipient heart transplant . 4 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel ticlopidine ) , sirolimus stainless steel , cobalt metal sensitivity contrast medium , adequately premedicated . 5 . Other medical illness ( e.g . skin cancer diagnose treat &gt; 3 year , neurological deficiency ) know history substance abuse ( alcohol etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy . 6 . Pregnant breastfeed woman woman fertile period take adequate contraceptive 7 . Chronic total occlusion ( TIMI 0 ) , leave main lesion , interventionrequired threevessel lesion , branch vessel diameter ≥ 2.5mm bypass lesion 8 . Patients expect comply 1 month DAPT； 9 . Compliance longterm single antiplatelet therapy unlikely； 10 . Active bleeding time inclusion； 11 . Patients require plan stag PCI procedure one week theindex procedure； 12 . Procedure plan require nonstudy stent , stand alone POBA standalone atherectomy； 13 . Reference vessel diameter &lt; 2.25 &gt; 4.0mm , vessel length &gt; 40mm； 14 . Cardiogenic shock； 15 . Participation another clinical trial ( 12 month index procedure ) . 16 . Those suitable attend trial evaluation doctor . OCT exclusion criterion Severe tortuous , calcify angulated coronary anatomy study vessel opinion investigator would result suboptimal image excessive risk complication placement OCT catheter Total occlusion thrombolysis myocardial infarction ( TIMI ) flow 0 , prior wire crossing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BuMA Supreme</keyword>
	<keyword>Xience V/Prime</keyword>
	<keyword>OCT</keyword>
	<keyword>neointima formation</keyword>
</DOC>